SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure following disappointing quarterly delivery figures and intensifying competition in the EV sector. Investors are actively debating the company's long-term prospects as capital increasingly shifts toward anticipation of the upcoming SpaceX IPO.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying following a strong quarterly earnings report that beat analyst expectations and provided a positive outlook for the year. The community is actively debating the stock's potential for a long-term turnaround fueled by the growing demand for energy storage and AI infrastructure, while some traders remain cautious about broader solar sector headwinds.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following the announcement of subscription price increases across all U.S. tiers, a move that analysts view as a strategic leverage of pricing power to fuel content investment. While the community is split between bullish sentiment over potential revenue gains and frustration regarding rising costs, traders are closely watching the stock for a breakout above the key 100 level as volume and institutional interest pick up.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing significant trading activity driven by persistent market speculation regarding a potential acquisition by major tech and space players like Amazon or SpaceX. The community is actively debating the strategic value of the company's spectrum assets and the impact of Apple's existing partnership, with many long-term shareholders dismissing lower buyout rumors as undervaluation.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is currently experiencing intense volatility and downward pressure following a recent reverse split, leaving the community deeply divided between frustrated long-term shareholders and short-sellers profiting from the decline. Investors are actively debating the company's long-term viability, citing concerns over management's silence on financial guidance and a lack of major sports network partnerships, while some traders continue to look for potential short-squeeze opportunities.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors in Luckin Coffee are closely watching for potential catalysts like a possible relisting and the strategic implications of the Blue Bottle Coffee acquisition, while debating the impact of ongoing market volatility on the company's valuation. Community discussion is dominated by long-term holders expressing frustration over price suppression, even as others continue to accumulate shares based on strong growth fundamentals and a belief in a coming rebound.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing a surge in investor attention as market sentiment shifts toward its critical role in AI infrastructure, with community focus centering on massive potential orders from major hyperscalers like Google and the company's pivot to high-volume semiconductor testing. Traders are closely watching for validation of these large-scale deployments, treating the stock as a high-conviction play on the structural expansion of AI-driven chip demand.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in patients with Prader-Willi syndrome. Investors are actively discussing the stock's significant valuation shift from a clinical-stage biotech to a commercial-stage company, while monitoring the potential for a long-term buyout in a sector seeing heavy consolidation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending as investors focus on the upcoming April 9th earnings report, with community sentiment split between high expectations for revenue growth from QNX-led automotive contracts and skepticism regarding historical guidance performance. Bulls are pointing to the integration of QNX in next-generation vehicle architectures as a major catalyst for long-term value, while shorts and skeptics continue to monitor the companys ability to move beyond stagnant revenue figures and prove sustained profitability.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix (ENVX) is currently experiencing high volatility as investors weigh the company's long-term potential in high-energy density batteries against ongoing manufacturing bottlenecks at its Malaysia facility. While community sentiment remains polarized, many participants are focused on the impact of a recent share repurchase program, the search for a major commercial purchase order, and whether the firm can successfully navigate production scaling to validate its silicon-anode technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating...

Oramed Pharmaceuticals (ORMP) to Release Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-oramed-pharmaceuticals-inc-stock...

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Declines By 16.2%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 540,151...

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Here's Why

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Above 50-Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>The reverse split would reduce the number of outstanding shares from about 18.3 million to around 1.5 million.</li><li>This marks the company’s second reverse stock split since March 2024, when it carried out a 1-for-7 consolidation.</li><li>Lifeward’s board also approved increasing the authorized share capital to 100 million shares.</li></ul>Shares of Lifeward (LFWD) slumped nearly 20% to their all-time low after the company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.<a href="https://stocktwits.com/symbol/LFWD">LFWD</a> stock will begin trading on a post-split basis the same day under the existing ticker symbol. The move is aimed at boosting the share price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement.<h2 class="st-heading-2">Outstanding Shares To Be Reduced To Around 1.5 Million</h2>The move follows shareholder approval in January, which authorized the board to determine whether to implement a reverse split of the company’s outstanding ordinary shares and, if so, to set the ratio within a range of 1-for-2 to 1-for-12, giving the board full discretion over the outcome.Under the reverse split, every 12 ordinary shares will automatically convert into one share, reducing outstanding shares from about 18.3 million to around 1.5 million. The board also approved increasing the authorized share capital to 100 million shares.This marks the company’s second reverse split in nearly two years. In March 2024, Lifeward completed a 1-for-7 reverse split of its ordinary shares, reducing the number of outstanding shares from around 60.1 million to about 8.6 million.<h2 class="st-heading-2">Partnership With Oramed For Protein Oral Delivery Technology</h2>In January, Lifeward partnered with Oramed Pharmaceuticals (ORMP) to integrate Oramed’s proprietary POD protein oral delivery technology into its platform.Under the terms of the deal, Oramed could acquire up to a 49.99% equity stake in Lifeward. The investment structure is expected to provide Lifeward with access to up to $47 million in capital through a combination of equity, convertible notes, milestone-based funding, and warrant coverage, supporting future growth initiatives.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Meanwhile, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours.Year-to-date, the stock has declined around 25%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spai-stock-reverses-gains-safe-pro-us-government-ai-contract/cZRN7XMR4x0">This AI-Based Defense Company Secured A US Government Contract – So, Why Did The Stock Reverse Pre-Market Gains?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LFWD Stock Sinks To Record Low On Second Reverse Split In Two Years

The company announced it would implement a 1-for-12 reverse stock split effective Feb. 24, 2026.

Equity

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest in January. As of January 30th, there was short interest totaling 644,912 shares, a growth of...

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average - Time to Sell?

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average - Should You Sell...

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 424,089...

Oramed and Lifeward Announce Strategic Transaction

Oramed and Lifeward Announce Strategic Transaction Oramed and Lifeward Announce Strategic Transaction PR Newswire NEW YORK, Jan. 13, 2026 Transaction Will TransferOramed's Oral Drug Delivery Platform...

Oramed Reports Fiscal Third Quarter 2025 Financial Results

Oramed Reports Fiscal Third Quarter 2025 Financial Results Oramed Reports Fiscal Third Quarter 2025 Financial Results PR Newswire NEW YORK, Nov. 17, 2025 Strong Nine-Month Performance Driven by...

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Current Price	$3.51
Prev Close	$3.42
Open	$3.41
Dividend Yield	0.00%
50-Day Moving Average	$3.40
Beta	0.78
Avg. Volume	125,956.93
PE Ratio	2.30

52-Week High	$3.76
52-Week Low	$1.82
Market Capitalization	$138.33M
EPS (Annual)	$1.50
Price to Book	0.67
Revenue Per Employee	$153,846.15

ORMP
Oramed Pharmaceuticals, Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ORMP News

ORMPOramed Pharmaceuticals, Inc